Figure 2. Silence of cPLAα decreases EGF-stimulated p-AKT and cell proliferation in HT-29 cells.

(A) immunoblot and (B) quantification of cPLA₂α and AKT in cells transfected with cPLA₂α siRNA or scramble control (10 nM for 72 h) with or without EGF treatment (20 ng/mL, 30 min). ^*P <0.05 vs. cells transfected with scramble control without EGF; ^#P <0.05 vs. cells transfected with scramble control with EGF. ^{^}P <0.05 cPLA₂α siRNA vs. cPLA₂α siRNA+EGF. (C) Arachidonic acid concentration in the intracellular and supernatant compartments measured by Mass Spectrometry. ^*P <0.05 vs. cells transfected with scramble control. (D) DNA content analysis by PI-Flow cytometry. ^*P <0.05 vs. cells transfected with scramble control.; (E) Immunoblot of HT-29 cells treated with 25 μM Efipladib for 72 h and/or 20 ng/mL EGF for 30 min before harvesting. (F) Densitometry quantification. ^*P <0.05 vs. DMSO, ^#P <0.05 vs. DMSO+EGF, n=3. All data expressed as Mean ± SD.